Abstract
Introduction Makawanpur district, one among 77 districts of Nepal, located in the Bagmati Province, has long been at high risk of contracting dengue. Since 2016 dengue cases were seen in considerable number in the district. Outbreak in 2022 became the worst scenario for this district. The goal of this study is to determine the dengue epidemic scenario in Makawanpur. The study focuses on the dengue outbreak of 2022 at the micro level for the rural municipalities, municipalities and metropolitan city of Makawanpur district.
Methods This study collected the peak epidemic five months of reported dengue cases in 2022 outbreak in Makawanpur from District Health Office (DHO).
Results In 2022 there were 5837 dengue cases reported from Makawanpur which is over 10% of total 54784 cases in that year. In five peak epidemic months of 2022 outbreak in Makawanpur, a total of 5595 cases found with 2514 females and 3081 males. Age-wise dengue infection shows that those between the ages of 20 and 60 are the most affected (3985) and those under the age of five are least affected (176).
Conclusions Geographical location, climatic factors, and socio-economic status of Makawanpur are favorable for prevalence of dengue and Makawanpur can be a potential dengue hub of Nepal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Central Department of Zoology, Tribhuvan University, recommended that the Health Office of Makawanpur district grant access to dengue data. DHO Makawanpur accepts the recommendation and grants access to the data, which are line-listed and available upon a genuine and reliable request. The datasets used in this study were individual-level data and had been de-identified before their use in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This updated version has a more descriptive nature and includes much more depth in the discussion.
Data Availability
All data produced in the present study are available upon reasonable request to the author.
